LUND, SWEDEN--(Marketwire - February 14, 2013) -
Events for the full year 2012
Laquinimod
* Phase III data presented at the AAN (64th Annual Meeting of the
American
Academy of Neurology)
* Application submitted for regulatory approval in the EU, milestone
payment
of USD 5 M from Teva
* Teva initiates a Phase III study in multiple sclerosis (the CONCERTO
study)
in the US
* Positive Crohn's Phase II data presented at the UEGW conference
* Teva expands the clinical development program to encompass new
indications
TASQ
* EUR 10 M milestone payment from Ipsen upon 600 patients enrolled in
Phase
III study
* overall survival data from Phase II study presented
* biomarker data presented at the ESMO conference
* Ipsen initiated two new Phase II trials; a "switch maintenance" in
prostate
cancer and
a second study into additional cancer forms
* Phase III study fully enrolled (1,245 patients); milestone payment of
EUR
10 M from Ipsen
ANYARA
* Phase II/III study in renal cell cancer concluded
* Results presented during Q1, 2013:
- study did not achieve primary clinical endpoint
- doubling of progression free survival and OS in 25 % of patients
- planning of the continued clinical development ongoing
57-57
* clinical trial of systemic sclerosis/scleroderma concluded
ISI
* focus on patent submissions H1 2013
* project proceeds as planned
Oct - Dec Jan - Dec
(MSEK) 2012 2011 2012 2011
---------------------------------------------------------------------------
* Net sales 91.5 3.3 227.9 234.6
* Operating profit/loss 5.5 -94.7 -163.2 -100.9
* Net profit/loss 0.1 -93.2 -175.0 -94.5
* Profit/loss per share (SEK) 0.00 -1.35 -2.54 -1.38
This report is also available at www.activebiotech.com
Active Biotech AB Year-end report Jan-Dec 2012:
http://hugin.info/1002/R/1678129/547591.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1678129]
